NLRP3 and familial dilated cardiomyopathy: Therefore, considering the essential role that the NLRP3 inflammasome plays in DCM [3], targeting the NLRP3 inflammasome pathway might be a plausible treatment to reduce the risk of developing heart failure in diabetes [10,37].